Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010).

[1]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[2]  A. Adams,et al.  Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. , 2013, The Journal of clinical endocrinology and metabolism.

[3]  P. Vestergaard,et al.  Increasing incidence of primary hyperparathyroidism in Denmark. , 2013, Danish medical journal.

[4]  B. Yawn,et al.  History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. , 2012, Mayo Clinic proceedings.

[5]  J. Yoo,et al.  Effect of reimbursement reductions on bone mineral density testing for female Medicare beneficiaries. , 2012, Journal of women's health.

[6]  G. Curhan,et al.  Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study , 2012, BMJ : British Medical Journal.

[7]  K. Mangano,et al.  Calcium intake in the United States from dietary and supplemental sources across adult age groups: new estimates from the National Health and Nutrition Examination Survey 2003-2006. , 2011, Journal of the American Dietetic Association.

[8]  K. Dodd,et al.  Estimation of total usual calcium and vitamin D intakes in the United States. , 2010, The Journal of nutrition.

[9]  Ning Yu,et al.  Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK , 2009, Clinical endocrinology.

[10]  S. Blalock,et al.  Trends and determinants of prescription medication use for treatment of osteoporosis. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  Sundeep Khosla,et al.  Incidence of Primary Hyperparathyroidism in Rochester, Minnesota, 1993–2001: An Update on the Changing Epidemiology of the Disease , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  I. Reid,et al.  Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. , 2005, The Journal of clinical endocrinology and metabolism.

[13]  I. Reid,et al.  Association between primary hyperparathyroidism and increased body weight: a meta-analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[14]  R. Stafford,et al.  National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. , 2004, Archives of internal medicine.

[15]  Karla Kerlikowske,et al.  Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results , 2004, Annals of Internal Medicine.

[16]  M. Schlumberger,et al.  Advances in diagnostic practices affect thyroid cancer incidence in France. , 2004, European journal of endocrinology.

[17]  R. Stafford,et al.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence. , 2004, JAMA.

[18]  J. Rastad,et al.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. , 2002, The Journal of clinical endocrinology and metabolism.

[19]  L. Melton,et al.  The epidemiology of primary hyperparathyroidism in North America. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  D. Meier,et al.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[22]  K. Bønaa,et al.  Primary hyperparathyroidism detected in a health screening. The Trømsø study. , 2000, Journal of clinical epidemiology.

[23]  G. Hawker,et al.  Patterns of use of the bone mineral density test in Ontario, 1992-1998. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  Md. Hasan Raza Ansari,et al.  Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. , 2000, The Journal of clinical endocrinology and metabolism.

[25]  W. O'Fallon,et al.  The Rise and Fall of Primary Hyperparathyroidism: A Population-Based Study in Rochester, Minnesota, 1965-1992 , 1997, Annals of Internal Medicine.

[26]  S. Khosla,et al.  Calcium infusion suggests a "set-point" abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. , 1993, The Journal of clinical endocrinology and metabolism.

[27]  O H Førde,et al.  The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase. , 1990, American journal of epidemiology.

[28]  T. Clemens,et al.  Suppression of parathyroid hormone secretion with oral calcium in normal subjects and patients with primary hyperparathyroidism. , 1990, The Journal of clinical endocrinology and metabolism.

[29]  A. F. Stewart,et al.  Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism. , 1985, New England Journal of Medicine.

[30]  R. Marcus,et al.  Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. , 1984, Annals of internal medicine.

[31]  S. Hodgson,et al.  Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. , 1980, The New England journal of medicine.

[32]  L. Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[33]  B. Yawn,et al.  American Journal of Epidemiology Practice of Epidemiology Use of a Medical Records Linkage System to Enumerate a Dynamic Population over Time: the Rochester Epidemiology Project , 2022 .